This series of AMI rapid test kits are used in the diagnosis of Acute Myocardial Infarction.
In the diagnosis of the Acute Myocardial Infarction, three rapid test kits are commonly used, which are Troponin-I (cTnI) Rapid Test Kit, CK-MB Rapid Test Kit and Myo Rapid Test Kit. These rapid test kits are all a rapid In-Vitro (IVD) rapid test based on the principle of chromatographic immunoassay for the qualitative detection of human Myoglobin, Creatine Kinase MB (CK-MB) and cardiac Troponin-I in serum or plasma.
These test kits are easy to perform, and takes as short as 10 minutes to be sure of the result, which make them suitable a Point of Care test (POCT) test kits.
AMI Triad Test
MYO/CK-MB/cTnI multi-3 test panel provides a qualitative analytical test result for the three AMI makers with one blood specimen. With this AMI test device, the detection of these three markers is complementary in diagnosis of myocardial infarction, since they detect cardiac tissue damage at different time structure and over a wide range of times after myocardial infarction. So the accuracy of the diagnosis will be higher than any of the three single test result.
What is AMI
Acute myocardial infarction (AMI) is commonly known as a heart attack. Myoglobin (MYO), Creatine Kinase MB (CK-MB) and cardiac Troponin I (cTnI) are the proteins appear in the bloodstream after cardiac injury.
MYO is released into the blood rapidly due to its relatively small size, the concentration which increases measurably above baseline within 2-4 hours post-infarct, peaking at 9-12 hours, and returning to baseline within 24-36 hours. The release of CK-MB can be detected within 3-8 hours after the onset of symptoms; peaks within 9 to 30 hours, and returns to baseline levels within 48 to 72 hours. The release pattern of cTnI is similar to CK-MB, with a difference that cTnI remains elevated for 6-10 days, thus providing for a longer window of detection for cardiac injury.